PROTACs: The Future of Leukemia Therapeutics

Zubair Anwar; Muhammad Shahzad Ali; Antonio Galvano; Alessandro Perez; Maria La Mantia; Ihtisham Bukhari; Bartlomiej Swiatczak

doi:10.3389/fcell.2022.851087

Frontiers in Cell and Developmental Biology (Sep 2022)

PROTACs: The Future of Leukemia Therapeutics

Zubair Anwar,
Muhammad Shahzad Ali,
Antonio Galvano,
Alessandro Perez,
Maria La Mantia,
Ihtisham Bukhari,
Bartlomiej Swiatczak

Affiliations

Zubair Anwar: Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, Uiniversity of Palermo, Palermo, Italy
Muhammad Shahzad Ali: Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Turin, Italy
Antonio Galvano: Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, Uiniversity of Palermo, Palermo, Italy
Alessandro Perez: Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, Uiniversity of Palermo, Palermo, Italy
Maria La Mantia: Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, Uiniversity of Palermo, Palermo, Italy
Ihtisham Bukhari: The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Bartlomiej Swiatczak: Department of History of Science and Scientific Archeology, University of Science and Technology of China, Hefei, China

DOI: https://doi.org/10.3389/fcell.2022.851087
Journal volume & issue: Vol. 10

Abstract

Read online

The fight to find effective, long-lasting treatments for cancer has led many researchers to consider protein degrading entities. Recent developments in PROteolysis TArgeting Chimeras (PROTACs) have signified their potential as possible cancer therapies. PROTACs are small molecule, protein degraders that function by hijacking the built-in Ubiquitin-Proteasome pathway. This review mainly focuses on the general design and functioning of PROTACs as well as current advancements in the development of PROTACs as anticancer therapies. Particular emphasis is given to PROTACs designed against various types of Leukemia/Blood malignancies.

Published in Frontiers in Cell and Developmental Biology

ISSN: 2296-634X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Science: Biology (General)
Website: https://www.frontiersin.org/journals/cell-and-developmental-biology

About the journal

Abstract

Keywords